All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-03-22T11:38:23.000Z

Dermatological toxicities associated with talquetamab in RRMM

Mar 22, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in relapsed/refractory multiple myeloma.

Bookmark this article

Talquetamab is a G protein-coupled receptor family C class 5 member D (GPRC5D) targeting bispecific antibody which was granted accelerated approval by the U.S. Food and Drug Administration and conditional marketing authorization by the European Commission. In both approvals, patients must have been treated with a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody; making talquetamab the first GPRC5D-targeted bispecific antibody to be approved for use in relapsed/refractory multiple myeloma (RRMM).

Here, we summarize a retrospective study published by Lery et al.1 in Journal of the American Academy of Dermatology on the dermatological toxicities associated with the use of talquetamab for the treatment of RRMM.

Study design/patient population1

  • A descriptive retrospective study conducted with patients treated in a single center from 2020–2022.
  • The cohort consisted of 14 patients with RRMM who had been exposed to talquetamab.
  • Eligibility criteria included both patients treated with talquetamab monotherapy or in combination.
  • Doses of talquetamab included subcutaneous infusion between 300 μg/kg and 800 μg/kg, administered weekly or fortnightly.

Key findings1

  • Of the 14 patients enrolled, 12 developed dermatological toxicities, with an overall incidence of 86% in this small cohort.
  • Nail changes were the most commonly occurring presentation, observed in 79% of patients, with onychomadesis in 57% (Figure 1).
  • The most frequent toxicity observed was xerostomia, occurring in 71% of patients.
  • Most toxicities were Grade 1 or 2, with no patients discontinuing treatment due to toxicities.
  • The dermatological toxicity profile remained consistent, regardless of the dose of talquetamab or combination administered.
  • In all cases, an improvement in hand-foot syndrome, xerosis, and fissures was achieved with skin-directed therapies, including high-potency steroids and moisturizers.

Figure 1. Dermatological toxicities* 

*Data from Lery, et al.1

Key learnings

  • Dermatological toxicities were observed in most patients treated with talquetamab, regardless of dose or combination therapy.
  • In most cases, the dermatologic toxicities were attributed to off-tumor on-target effects due to the high expression of GPRC5D in hard-keratinized structures such as the nails.
  • This trial included a small cohort from a single center, making the data less generalizable. However, the findings highlight the need for further research in patients treated with talquetamab.

  1. Lery M, Perrot A, Ortiz-Brugues A, et al. Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamab. J Am Acad Dermatol. 2024;90(2):376-377. DOI: 1016/j.jaad.2023.08.094

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
16 votes - 16 days left ...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox